Effects of niacin on atherosclerosis and vascular function

Current Opinion in Cardiology

Volumn 26, Issue 1, 2011, Pages 66-70

  Ruparelia, Neil ^a   Digby, Janet E ^a   Choudhury, Robin P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Atherosclerosis; Endothelial function; Niacin; Nicotinic acid

Indexed keywords

C REACTIVE PROTEIN; COLESTIPOL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PLACEBO; SIMVASTATIN;

ARTICLE; ATHEROSCLEROSIS; CELL STRAIN HEPG2; CORONARY ARTERY DISEASE; DRUG MEGADOSE; FOLLOW UP; HEART INFARCTION; LIPID METABOLISM; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVASCULARIZATION; STROKE;

ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; LIPID METABOLISM; NIACIN;

EID: 79951683548     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283410c16     Document Type: Article

References (51)

1. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955; 54:558-559.
2. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255. (Pubitemid 17208898)
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
4. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1:16-19.
5. Grover SA, Kaouache M, Joseph L, et al. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch Intern Med 2009; 169:1775-1780.
6. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260:641-651.
7. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990; 85:1234-1241. (Pubitemid 20123768)
8. Rong JX, Li J, Reis ED, et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001; 104:2447-2452. (Pubitemid 33108379)
9. Choudhury RP, Rong JX, Trogan E, et al. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol 2004; 24:1904-1909. (Pubitemid 39350311)
10. Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009; 54:1787-1794.
11. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361:2113-2122.
12. AIM-HIGH: niacin plus statin to prevent vascular events. http://clinicaltrials.gov/ct2/show/NCT00120289. [Accessed 1 June 2010]
13. HPS2-THRIVE: a randomized trial of the long-term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant. http://clinicaltrials.gov/ct2/show/NCT00461630. [Accessed 1 June 2010]
14. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298. (Pubitemid 20364735)
15. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990; 264:3013-3017.
16. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223:405-418.
17. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592. (Pubitemid 33126837)
18. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512-3517. (Pubitemid 39612564)
19. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006; 22:2243-2250. (Pubitemid 44789989)
20. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010; 55:2721-2726.
21. Blumenthal RS, Michos ED. The HALTS trial: halting atherosclerosis or halted too early? N Engl J Med 2009; 361:2178-2180.
22. Kastelein JJ, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med 2009; 361:2180-2183.
23. Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000; 2:36-46.
24. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278:9869-9874. (Pubitemid 36800490)
25. Soga T, Kamohara M, Takasaki J, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003; 303:364-369. (Pubitemid 36338250)
26. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med 2003; 9:352-355. (Pubitemid 36362793)
27. Soudijn W, van Wijngaarden I, Ijzerman AP. Nicotinic acid receptor subtypes and their ligands. Med Res Rev 2007; 27:417-433. (Pubitemid 46668940)
28. Zhang Y, Schmidt RJ, Foxworthy P, et al. Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun 2005; 334:729-732. (Pubitemid 40982427)
29. Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci 2006; 27:384-390. (Pubitemid 43963187)
30. Van der Hoorn JW, de Haan W, Berbee JF, et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE-3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008; 28:2016-2022.
31. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 1999; 19:1051-1059. (Pubitemid 29177355)
32. Ganji SH, Tavintharan S, Zhu D, et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004; 45:1835-1845. (Pubitemid 40990875)
33. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010; 74:213-220.
34. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979. (Pubitemid 27152782)
35. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843. (Pubitemid 30165206)
36. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344:1959-1965. (Pubitemid 32568149)
37. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31:1460-1465. (Pubitemid 28273285)
38. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343:1139-1147.
39. Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002;105:1412-1415. (Pubitemid 34263269)
40. Kuvin JT, Dave DM, Sliney KA, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006; 98:743-745. (Pubitemid 44301006)
41. Spiroglou SG, Kostopoulos CG, Varakis JN, Papadaki HH. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J Atheroscler Thromb 2010; 17:115-130.
42. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291:1730-1737. (Pubitemid 38489895)
43. Schulze MB, Shai I, Rimm EB, et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54:534-539.
44. Kojima S, Funahashi T, Sakamoto T, et al. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 2003; 89:667.
45. Westphal S, Borucki K, Taneva E, et al. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007; 193:361-365. (Pubitemid 47058098)
46. Plaisance EP, Lukasova M, Offermanns S, et al. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am J Physiol Endocrinol Metab 2009; 296:E549-E558.
47. Digby JE, McNeill E, Dyar OJ, et al. Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis 2010; 209:89-95.
48. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117:185-194. (Pubitemid 46048465)
49. Mahabadi AA, Reinsch N, Lehmann N, et al. Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis. Atherosclerosis 2010; 211:195-199.
50. Wu BJ, Yan L, Charlton F, et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol 2010; 30:968-975.
51. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J AmColl Cardiol 2010; 55:1283-1299.